Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Giménez Arnau, Anna Mariaca
- dc.date.accessioned 2018-01-11T08:20:47Z
- dc.date.issued 2017
- dc.description.abstract Chronic spontaneous urticaria (CSU) is characterized by the recurrence of itchy hives and/or angioedema for greater than six weeks, with no known external trigger. Omalizumab, a humanized, recombinant, monoclonal anti-IgE antibody, is the only approved add-on therapy for H1-antihistamine refractory CSU patients. Areas covered: The objective of this article is to discuss the mechanism of action, pharmacokinetics and pharmacodynamics of omalizumab for the treatment of CSU. The review also summarizes efficacy and safety data from proof-of-concept, phase II (X-CUISITE, MYSTIQUE), and pivotal phase III omalizumab studies (ASTERIA I, ASTERIA II, and GLACIAL). Expert opinion: Omalizumab is a clinically effective and safe biological therapy for treating H1-antihistamine refractory CSU patients. It significantly reduces CSU symptoms (hives, itch and angioedema), and improves patient health-related quality of life. While omalizumab is already integral to the treatment of antihistamine refractory CSU, widespread use will depend on legal and economic factors, as well as improvements in the early and accurate diagnosis of CSU patients who would benefit from treatment.
- dc.format.mimetype application/pdfca
- dc.identifier.citation Giménez-Arnau AM. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety. Expert Opin Biol Ther. 2017 Mar;17(3):375-385. DOI: 10.1080/14712598.2017.1285903
- dc.identifier.doi http://dx.doi.org/10.1080/14712598.2017.1285903
- dc.identifier.issn 1471-2598
- dc.identifier.uri http://hdl.handle.net/10230/33611
- dc.language.iso eng
- dc.publisher Taylor & Francis (Routledge)ca
- dc.relation.ispartof Expert Opinion on Biological Therapy. 2017 Mar;17(3):375-85
- dc.rights © Taylor & Francis. This is an electronic version of an article published in Giménez-Arnau AM. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety. Expert Opin Biol Ther. 2017 Mar;17(3):375-385. Expert opinion on biological therapy is available online at: www.tandfonline.com http://www.tandfonline.com/doi/abs/10.1080/14712598.2017.1285903
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.subject.keyword Anti-IgE
- dc.subject.keyword Chronic idiopathic urticaria
- dc.subject.keyword Chronic spontaneous urticaria
- dc.subject.keyword Chronic urticaria
- dc.subject.keyword Omalizumab
- dc.subject.other Urticària -- Tractament
- dc.title Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safetyca
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/acceptedVersion